Effect of Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography : a Monocentric, Prospective, Randomized and Open-label Phase II Trial
Latest Information Update: 07 May 2024
At a glance
- Drugs Evolocumab (Primary)
- Indications Atherosclerosis; Coronary artery disease
- Focus Therapeutic Use
- Acronyms MICROPROTECT
Most Recent Events
- 25 Aug 2021 Status changed from not yet recruiting to recruiting.
- 20 Mar 2020 New trial record